Table 1 Baseline clinical patient characteristics
Control (n = 9) | Treated (n = 9) | |
|---|---|---|
Age at diagnosis (years) | 50.0 (32.0, 68.0) | 51.0 (42.0, 83.0) |
Age at enrollment (years) | 55.0 (35.0, 83.0) | 59.0 (43.0, 83.0) |
ER (%) | 90.0 (0.0, 100.0) | 90.0 (0.0, 100.0) |
PR (%) | 50.0 (0.0, 95.0) | 0.0 (0.0, 80.0) |
HER2 amplification | 3 (33.3%) | 0 (0.0%) |
Ki67 (%) | 37.5 (10.0, 50.0) | 37.5 (7.5, 80.0) |
Histology | ||
Ductal | 7 (77.8%) | 6 (66.7%) |
Lobular | 1 (11.1%) | 3 (33.3%) |
Mucinous/neuroendocrine | 1 (11.1%) | 0 (0.0%) |
Metastasis sites | ||
Liver | 6 (66.7%) | 5 (55.6%) |
Lung | 5 (55.6%) | 3 (33.3%) |
Bone | 7 (77.8%) | 9 (100.0%) |
Others | 7 (77.8%) | 8 (88.9%) |
Number of previous treatment lines | 2.0 (1.0, 5.0) | 1.0 (0.0, 9.0) |
